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ABSTRACT: Protein kinases are essential regulators of most cellular
processes and are involved in the etiology and progression of multiple
diseases. The cdc2-like kinases (CLKs) have been linked to various
neurodegenerative disorders, metabolic regulation, and virus
infection, and the kinases have been recognized as potential drug
targets. Here, we have developed a screening workﬂow for the
identiﬁcation of potent CLK2 inhibitors and identiﬁed compounds
with a novel chemical scaﬀold structure, the benzobisthiazoles, that
has not been previously reported for kinase inhibitors. We propose
models for binding of these compounds to CLK family proteins and
key residues in CLK2 that are important for the compound
interactions and the kinase activity. We identiﬁed structural elements
within the benzobisthiazole that determine CLK2 and CLK3
inhibition, thus providing a rationale for selectivity assays. In
summary, our results will inform structure-based design of CLK family inhibitors based on the novel benzobisthiazole scaﬀold.
Protein kinases control and modulate a wide variety ofbiological processes through their catalytic activity,1,2
including signal transduction and gene splicing. Gene splicing
is controlled by the splicing machinery and the assembly of a
spliceosome. Spliceosome assembly is mediated by multiple
splicing factors, including the hnRNP family of proteins and the
serine and arginine rich (SR) proteins.3 A key event is the
phosphorylation of SR proteins that leads to their nuclear
translocation and therefore activation. Kinases that mediate this
phosphorylation event are members of the SRPK (SR protein
kinase) family, members of the CLK (cdc2-like kinase) family,
and topoisomerase 1. The CLKs are dual-speciﬁcity kinases
(tyrosine and serine/threonine kinases) of the CMGC family
(cyclin-dependent kinases, mitogen-activated kinases, glycogen
synthase kinases, and CDK-like kinases). There are four
mammalian isoforms, CLK1−4, with diﬀerent substrate targets.
CLK activity is controlled by autophosphorylation on multiple
serine residues4 and phosphorylation at serine 34, threonine
127, and threonine 344 by AKT1/2.5 Members of the CLK
family of proteins, most notably, CLK1 and CLK2, are
promising drug targets in a variety of diseases. For instance,
it has been observed that CLK2 is an insulin-regulated
suppressor of hepatic gluconeogenesis.6 Additionally, it
suppresses hepatic fatty acid oxidation and ketogenesis.7 It
has also been proposed that CLK2 is a potential drug target for
Alzheimer’s disease,8,9 Gaucher’s disease,10 and a form of
mental retardation, ataxia and atrophy of the brain.11 More
recently, it has been shown that CLK regulates HIV virus
production by modulating splicing of the provirus and aﬀecting
gene expression of viral genes.12 CLK1 inhibitors are also
eﬀective in interfering with inﬂuenza virus infection,13
suggesting a more general role for CLK inhibitors as antiviral
agents. Therefore, there is a demand for developing CLK
inhibitors and activators on various disease settings. A number
of clinical trials aiming to modify alternative splicing in diverse
diseases such as diabetes, acute myeloid leukemia, HIV
infection, and cystic ﬁbrosis (see www.clinicaltrials.gov) are
ongoing or have been completed. To date, several small
molecules targeting SR proteins, topoisomerase I, and kinase
inhibitors for SRPKs and CLKs have been developed14
(summarized in ref 15). However, most identiﬁed inhibitors
are potent inhibitors of multiple CLK family members with
strongest inhibition of CLK1. Structure−activity relationship
studies may aid in the design of more selective compounds.
Here, we studied structural determinants in CLK2 that
contribute to ATP binding and catalytic activity to rationalize
compound binding. We conducted small molecule screening
for the identiﬁcation of novel CLK2 inhibitors and investigated
the selectivity of the compounds on the basis of the kinase
crystal structures, the molecular docking, and kinase inhibition
assays. Interestingly, we identiﬁed a class of benzobisthiazole
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derivatives, a novel chemical scaﬀold structure, that exhibit
speciﬁc proﬁles among members of the CLK family.
■ EXPERIMENTAL PROCEDURES
Plasmid Cloning. cDNA encoding the CLK2 catalytic
domain (CLK2cd, amino acids 140−496) was obtained by
polymerase chain reaction (PCR) using full-length human
CLK2 as a template and BamHI-CLK2 and CLK2-NotI as
primers (Supplementary Table 1). The PCR fragment was
inserted into bacterial expression vector pGEX6P-1 (GE
Healthcare, catalog no. 27-4597-01) using BamHI and NotI,
in-frame with an N-terminal GST tag creating pGEXCLK2cd.
To generate the CLK2cdK193A (pGEXCLK2cdK193A) and
CLK2cdD290A (pGEXCLK2cdD290A) mutan t s ,
pGEXCLK2cd was used as a template and two pairs of
primers, CLK2-K193A-R and CLK2-K193A-F and CLK2-
D290A-R and CLK2-D290A-F, were used. All PCRs were
conducted for 30 cycles using Pyrobest DNA polymerase
(Takara, R005A). To create double mutant CLK2cdK193A/
D290A, pGEXCLK2cdK193A and pGEXCLK2cdD290A plas-
mids were digested with NcoI and NotI and the resulting longer
and shorter DNA fragments from digestion of pGEXCK2cd-
K193A and pGEXCLK2cdD290A, respectively, were ligated,
creating pGEXCLK2cdK193A/D290A. All the clones were
veriﬁed by DNA sequencing.
Protein Expression and Puriﬁcation. Expression plas-
m id s pGEXCLK2cd , pGEXCLK2cdK193A , and
pGEXCLK2cdK193A/D290A were transformed into Escher-
ichia coli BL21(DE3)-R3-lambda-PPase obtained from the
Structural Genomics Consortium (Oxford University, Oxford,
U.K.). The proteins were induced by 0.1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) at 18 °C overnight. GST-tagged
proteins were puriﬁed using Glutathione Sepharose 4B (GE
Healthcare, catalog no. 17-0756-01) eluted with 50 mM Tris-
HCl (pH 8.0), 150 mM NaCl, 0.5 mM EDTA, 0.1 mM EGTA,
10 mM reduced glutathione, and 1 mM DTT. The proteins
were further puriﬁed by using Amicon ultracentrifugal ﬁlter
units ultra-15, with a 30 kDa molecular weight cutoﬀ (Sigma-
Aldrich, catalog no. Z717185-8EA), and stored at −80 °C in 50
mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.5 mM EDTA, 0.1
mM EGTA, 33% glycerol, and 1 mM DTT.
Protein concentrations were determined with a sodium
dodecyl sulfate (SDS)−polyacrylamide gel (4 to 20% gradient,
Bio-Rad, catalog no. 456-1096) electrophoresis of the puriﬁed
proteins and quantiﬁcation of the Coomassie-stained gel using
ImageJ protein quantiﬁcation (http://openwetware.org/wiki/
Protein_Quantiﬁcation_Using_ImageJ), with bovine serum
albumin (BSA) (abcam, ab102536) as a standard. Three
diﬀerent amounts of proteins were loaded on each gel, and the
total intensity of each band corresponding to the puriﬁed
enzyme was calculated by comparing the band intensity to the
corresponding BSA standard curve.
Analysis of Enzyme Kinetics for CLK2cd and Its
Mutants. Puriﬁed GST-CLK2cd, GST-CLK2cdK193A, and
GST-CLK2cdK193A/D290A at 14.5, 72.46, and 362.32 nM,
respectively, were incubated with 2-fold serial dilutions of a
mixture of ATP (Sigma, catalog no. A7699) and S6K peptide
(KRRRLASLR) (SignalChem, catalog no. S05-58) in a 1:5 ratio
(ATP:S6K) from 20 to 0.15 μM in 10 μL of kinase assay buﬀer
A [25 mM Tris-HCl (pH 7.5), 0.1 mg/mL BSA, 10 mM
MgCl2, 0.5 mM NaO3V, 5 mM β-glycerophosphate, and 2 mM
DTT] in white 384-well plates (Greiner bio-one, catalog no.
781904) for 1 h at 30 °C. Ten microliters of Kinase-Glo
(Promega, catalog no. V6713) was then added to the reaction
mixture and incubated for 5 min at room temperature before
the luminescence was read in the PerkinElmer Envision II
instrument. The initial velocity (molar per second, y axis) was
deﬁned as the change in the concentration of ATP used for
phosphorylated S6K, which was plotted versus the concen-
tration of substrate ATP before reaction (molar, x axis). The
curves were then ﬁtted using the nonlinear regression method
in R software, from which the Vmax and Km (Michaelis constant)
for each enzyme−substrate reaction were derived. The kcat
(catalytic constant) was determined by dividing Vmax by the
enzyme concentration. The catalytic eﬃciency is deﬁned as kcat/
Km (inverse molar liter per second).
High-Throughput Screening. A small molecule inhibitor
library consisting of 1600 compounds was obtained from LIFE
Chemicals (Kiev, Ukraine). These compounds are part of the
CUTE kinase collection that was predicted by in silico proﬁling
against a panel of targets and includes potent kinase inhibitor
compounds.16 Compounds were dissolved as 10 mM stocks in
DMSO and stored at room temperature, in the presence of 5%
humidity and 5% oxygen in the dark in a Roylan Storage Pod
system. Compounds were dispensed into white 384-well plates
using the Labcyte Echo520 instrument at a ﬁnal concentration
of 10 μM. Next, 5 μL of 144.92 nM puriﬁed GST-CLK2cd in
kinase assay buﬀer A was added to the compounds, incubated
for 10 min at room temperature prior to addition of 5 μL of a 2
μM ATP/10 μM S6K peptide mixture, and incubated again for
60 min at room temperature. Subsequently, 10 μL of Kinase-
Glo was added to the wells, and the plates were analyzed after
10 min on the Envision II multilabel plate reader
(PerkinElmer). TG003 (Sigma, catalog no. T5575) and
DMSO were used as a positive control and a negative control,
respectively. The percentage of inhibition is equal to 100 −
[(total ATP before assay − remaining ATP in assay with
compound)/(total ATP before assay − remaining ATP in assay
with DMSO) × 100]. The compounds that gave ≥50%
inhibition were selected for IC50 analysis. NR9 was obtained
from Enzo Life Sciences (catalog no. ALX-270-463-M001).
For kinase inhibition assays, the ﬁnal concentrations of the
enzymes were 15, 14.5, 14.5, and 8.8 nM for CLK1, CLK2,
CLK3, and Dyrk1A (Invitrogen, catalog no. PV3785),
respectively. The compound concentrations ranged from
15503 to 121 nM and from 1550 to 12 nM. The RS domain-
derived peptide (GRSRSRSRSR) (Anaspec, catalog no. 61722)
for CLK1 and CLK3, Dyrktide (RRRFRPASPLRGPPK)
(Anaspec, catalog no. 62698) for Dyrk1A, and S6K peptide
for CLK2 were used as substrates at a concentration of 5 μM.
Luciferase Inhibition Assay. For analysis of luciferase
inhibition, 10 μL of luciferase reagent (Kinase-Glo, Promega)
was added to 10 μL of a mixture consisting of 1 μM ATP and 5
μM S6K and 10 μM compound (potential kinase inhibitor) in
buﬀer A in the absence of kinase and incubated for 10 min at
room temperature in a white well plate before the luminescence
was read. The percentage of inhibition is equal to
(luminescence in the assay without compound − luminescence
in the assay with compound)/(luminescence in the assay
without compound) × 100.
Kinase Proﬁling. 3A5 and 5E4 were sent to the
International Centre for Kinase Proﬁling at the MRC Protein
Phosphorylation and Ubiquitylation Unit for proﬁling (as
described in ref 17). Compounds were proﬁled against 140
kinases using a radioactive ([33P]ATP) ﬁlter binding assay at a
Biochemistry Article
DOI: 10.1021/acs.biochem.5b01128
Biochemistry 2016, 55, 608−617
609
concentration of 1 μM. Results were obtained as inhibition of
kinase activity and are listed in Supplementary Table 2.
Molecular Docking. In silico docking of kinase inhibitors
and ATP into the ATP binding pocket of CLK2 {human X-ray
structure [Protein Data Bank (PDB) entry 3NR9] cocrystal-
lized with ligand (5Z)-5-(quinolin-6-ylmethylidene)-2-[(thio-
phen-2-ylmethyl)amino]-1,3-thiazol-4(5H)-one (ligand code,
NR9)} and CLK3 (human CLK3 X-ray structure (PDB entry
2WU6) cocrystal l ized with l igand 5-amino-3-{[4-
(aminosulfonyl)phenyl]amino}-N-(2,6-diﬂuorophenyl)-1H-
1,2,4-triazole-1-carbothioamide (ligand code, DKI)) was
performed using GOLD.18,19 The binding site used in the
docking study was deﬁned by residues within 6 Å of the
cocrystallized ligand. Molecules 3A5, 5E4, 5F4, and NR9 were
docked against 3NR9 and 2WU6 using GOLD. The four lowest
conformations of each molecule were generated by MOE
[Molecular Operating Environment (MOE), 2014.09, Chem-
ical Computing Group Inc., Montreal, QC] as initial structures
for GOLD docking. GOLD docking was performed using
GOLD’s genetic algorithm (GA) with scoring function
ChemScore20 as it is more suitable for the kinase family. The
three best binding poses from each inhibitor, determined by
their ﬁtness scores, were saved and examined visually for both
CLK2 and CLK3. The cocrystallized ligand (NR9-3NR9 and
DKI-2WU6) molecules were docked back into the protein
structures as a validation test. In all the docking poses for 3NR9
(CLK2) and 2WU6 (CLK3), GOLD correctly predicted the
binding conformation as that in the X-ray crystallographic
structure.
■ RESULTS
Residues K193 and D290 in CLK2 Are Required for
Catalytic Activity. To identify small molecule inhibitors of the
CLK family of proteins, we developed an in vitro kinase assay
for CLK2 that is amenable to high-throughput drug screening.
We generated N-terminal GST fusions of the wild-type (WT)
CLK2 catalytic domain (GST-CLK2cd) and mutant forms that
interfere with ATP binding or catalytic activity (GST-
CLK2cdK193A or GST-CLK2cdK193A/D290A, respectively)
(Figure 1A), expressed them in E. coli BL21(DE3)-R3-lambda-
PPase, and puriﬁed them using Glutathione Sepharose 4B
(Figure 1B). To measure the activities of WT CLK2 and CLK2
mutants, we determined the conversion of ATP substrate at
diﬀerent concentrations at 30 °C for 1 h. GST-CLK2cdK193A/
D290A and GST-CLK2cdK193A showed a substrate con-
version signiﬁcantly slower than that of GST-CLK2cd (Figure
1C). We calculated the catalytic rates of the enzyme and the
mutants (Figure 1D) and found that the Kcat/Km values of
GST-CLK2cdK193A/D290A, GST-CLK2cdK193A, and GST-
CLK2cd were 2.6 × 10−4, 27.8 × 10−4, and 143.2 × 10−4 M−1
s−1, respectively, which indicated that the K193A mutation or
K193A/D290A double mutation leads to the catalytic activity
Figure 1. Plasmid construction, protein puriﬁcation, and catalytic activity analysis of CLK and its mutants. (A) Schematic diagram of GST-CLKcd
(GST-tagged CLK catalytic domain) and GST-CLK2cd mutants used in this study. The arginine rich domain in wild-type CLK2 is depicted as a
checkered box and the catalytic domain (cd) as black box. Residues 193 and 290 in the catalytic domain of CLK2 are highlighted. (B) Puriﬁcation of
GST-CLKcd and GST-CLK2cd mutants. The catalytic domains of CLK1, CLK2, CLK3, CLK2K193A, and CLK2K193A/D290A were tagged with
GST, subjected to SDS−PAGE, and stained with Coomassie brilliant blue. The arrow indicates the bands corresponding to 1 μg of the puriﬁed
enzymes. (C) Catalytic activities of CLK2 and mutants. Blue diamonds, red circles, and green triangles depict data for GST-CLK2cd, GST-
CLK2cdK193A, and GST-CLK2cdK193A/D290A, respectively. The catalytic activity was determined after incubation of the puriﬁed kinase with
substrate at 30 °C as described in Experimental Procedures. The initial velocity (y axis) was deﬁned as the change in the concentration of ATP used
for phosphorylated S6K, which was plotted vs the concentration of substrate ATP before reaction (x axis). (D) Enzyme kinetics of GST-CLK2cd
and its mutants were determined as described for panel C and quantiﬁed.
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of CLK2 being decreased >5- or >54-fold, respectively. We
therefore propose that both K193 and D290 contribute to the
catalytic activity of CLK2.
Identiﬁcation of Small Molecule Inhibitors of CLK2.
Next, we screened a small molecule inhibitor library consisting
of 1600 compounds from LIFE Chemicals that were predicted
to be kinase inhibitors by in silico proﬁling.16 The screening was
conducted at a ﬁnal concentration of 10 μM in quadruplicate.
Using TG003, a known inhibitor of CLK1 and CLK2 activity21
as a positive control, we measured the conversion of ATP using
a luciferase-based in vitro kinase assay as described in
Experimental Procedures. Comparing TG003 inhibition to
that of DMSO-treated controls, we determined a Z prime factor
of 0.71 (Figure 2A,B), which we found suitable for high-
throughput screening.
Figure 2. High-throughput screening (HTS) for CLK2 inhibitors. (A) Normalized screening data for 1600 compounds from a LIFE Chemicals
library. Each plate contains 80 compounds in four replicates, 32 replicates for substrate (ATP+S6K) only, and 16 replicates each for positive and
negative control samples. The cellHTS230 software package (R, Bioconductor) was used to process the data. Raw data points were normalized with
the normalized percent inhibition (NPI) method. (B) Kernel density estimate functions were calculated from the normalized positive and negative
control values, and a Z′ factor was calculated using the cellHTS2 Bioconductor package. (C) Chemical structures of TG003 and the hit compounds.
The percentage of inhibition of the compounds at 10 μM on CLK2 is shown in parentheses. (D) Chemical structure of the two isomeric
benzobisthiazole scaﬀolds.
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Hits were initially ranked by percentage of inhibition
compared to DMSO control. Seventeen hits were identiﬁed
as potential inhibitors of CLK2 at ≥50% inhibition in the
primary screen (Figure 2C). Among the hit compounds, four
benzobisthiazoles were identiﬁed (3A5, 4G9, 5E4, and 5F4).
Because some compounds may reduce luciferase activity or
elicit autoluminescence, we tested all hits for potential
interference with luciferase activity. Compounds were incu-
bated with ﬁreﬂy luciferase in the absence of kinase, and the
percentage of inhibition of luciferase activity was measured
(Table 1). Most compounds did not signiﬁcantly reduce or
increase luciferase activity, with the exception of benzobisthia-
zole 4G9 that reduced luciferase activity by 47.8 ± 2.1%. We
are therefore unable to assess the CLK2 inhibition for 4G9 with
the assay used. The other three benzobisthiazoles (3A5, 5E4,
and 5F4) were then taken forward for further studies as
potential inhibitors of CLK2 activity (Figure 2D). To
determine the IC50 values for TG003 and benzobisthiazoles
3A5, 5E4, and 5F4, we assayed dose−response curves of the
compounds from 15503 to 121 nM and from 1550 to 12 nM.
The IC50 values for CLK2 inhibition by TG003, 3A5, 5E4, and
5F4 were determined to be 353, 68, 174, and 127 nM,
respectively (Table 2). In conclusion, compounds 3A5, 5E4,
and 5F4 are potent inhibitors of CLK2 activity with IC50 values
similar to or slightly better than that of known inhibitor TG003.
Kinase Proﬁling. To determine the speciﬁcity for the novel
CLK2 inhibitors, we proﬁled compounds 3A5 [N-(2-methyl-
[1,3]thiazolo[5,4-e][1,3]benzothiazol-7-yl)-1,3-benzothiazole-
6-carboxamide] and 5E4 {N-[7-(methylsulfanyl)[1,3]thiazolo-
[4,5-g][1,3]benzothiazol-2-yl]-2-furamide} against a Premier
Screen-kinase panel (Supplementary Table 2) (http://www.
kinase-screen.mrc.ac.uk/premier-screen).17 The panel used
consists of 140 kinases (138 human kinases, one rat kinase,
and one Tribolium castaneum kinase) and covers the whole
breadth of potential kinases. Compounds 5E4 and 3A5 were
conﬁrmed as very potent inhibitors of CLK2 with 97%
inhibition at 1 μM. Furthermore, both compounds displayed
a strong inhibitory activity toward the related kinase DYRK1A
(97% for 5E4 and 84% for 3A5) and some inhibitory activity
toward other kinases (see Supplementary Table 2). Other CLK
family members were not presented in the panel. Overall, these
compounds display high potency toward the CLK family of
kinases.
Inhibitor Binding and Speciﬁcity against CLKs and
Dyrk1A. Next, we were interested in assessing the selectivity of
the benzobisthiazoles toward other CLK family members and
the closely related DYRK1A kinase. We analyzed the inhibitory
eﬀect of 3A5, 5E4, 5F4, and two known inhibitors of CLK2
(NR9 and TG003) against CLK1, CLK2, CLK3, and Dyrk1A
(Supplementary Figure S1). We determined the IC50 values for
TG003 to be 49, 353, >3000, and 204 nM for CLK1, CLK2,
CLK3, and Dyrk1A, respectively (Table 2). Compounds 5E4
and 5F4 were equally eﬀective inhibitors against the tested
kinases. Among the tested compounds, 3A5 was the most
potent inhibitor for the kinases with IC50 values of 51, 68, 346,
and 260 nM for CLK1, CLK2, CLK3, and Dyrk1A, respectively.
NR9 had the poorest inhibitory eﬀect against the kinases with
an IC50 value of 553 nM against CLK2.
To understand the preference of the compounds in
inhibition of CLK1 and CLK2 over other related kinases, we
compared the kinase domain structures of CLK1, CLK2, CLK3,
and DYRK1A to identify key residues that contribute to
catalytic activity. Analysis of the structural superimposition of
the protein kinase domains (Figure 3A) revealed root-mean-
squared (rms) distances of the aligned atoms of 0.598, 0.556,
0.734, and >1.2 Å for CLK1 (PDB entry 2VAG) and CLK3
(PDB entry 2WU6), CLK1 and CLK2 (PDB entry 3NR9),
CLK2 and CLK3, and Dyrk1A (PDB entry 4MQ1) and CLKs,
respectively. These results indicate that the catalytic domain of
CLK2 is most similar to that of CLK1. This is in agreement
with the IC50 values for the identiﬁed inhibitors that target both
CLK1 and CLK2 equivocally.
The crystal structure of CLK2 allows the identiﬁcation of
residues that line the ATP binding pocket and may thus
contribute to compound binding. Using Pymol software22 for
surface viewing of the CLK2 structure (PDB entry 3NR9), we
identiﬁed multiple amino acid residues that contribute to the
formation of hydrophilic and hydrophobic patches of the ATP
binding pocket (Figures 3 and 4). Structural studies of CLK1 in
complex with inhibitors V25 (PDB entry 2VAG) and DBQ
(PDB entry 1Z57) allowed us to identify conserved residues
that contribute to inhibitor binding, including F172, K191,
E292,14,23−25 and F241.26 Together with CLK2 structural data,
this suggests that the corresponding residues F174, K193, F243,
and E294 in CLK2 play a signiﬁcant role in compound binding.
We then examined the binding of the benzobisthiazole
moiety in CLK2 by in silico molecular docking. For 3A5, the
Table 1. Inhibition of Luciferase by Hit Compounds at 10 μMa
TG003 1C11 2A4 3A5 3B5 4B9 4G9 5E4 5E11
% inhibition 13.4 ± 1.8 8.1 ± 1.8 17.5 ± 4.5 6.7 ± 2.8 26 ± 1.1 20.4 ± 1.6 47.8 ± 2.1 29.7 ± 2.9 26.4 ± 2.4
5F4 7C4 8A6 8B5 9C6 13D3 17F6 18B6 18H3
% inhibition 23.6 ± 1.5 19.6 ± 3.6 18.8 ± 1.6 0 ± 6.2 5.6 ± 4.0 0 ± 2.4 21.9 ± 0.2 17.5 ± 2.2 21.1 ± 2.2
aLuciferase inhibition was measured by combining 10 μL of luciferase reagent with 10 μL of a mixture consisting of 1 μM ATP and 5 μM S6K and
10 μM compound (potential kinase inhibitor) in reaction buﬀer after incubation for 10 min at room temperature. The percentage of inhibition is
equal to (luminescence in the assay without compound − luminescence in the assay with compound)/(luminescence in the assay without
compound) × 100.
Table 2. IC50 Values for Inhibitors for CLK Family
Membersa
TG003 NR9 3A5 5E4 5F4
CLK1 (nM) 49 390 51 277 273
CLK2 (nM) 353 553 68 174 127
CLK3 (nM) >3000 >3000 346 >3000 >3000
DYRK1A (nM) 204 596 260 334 213
aIC50 values were determined for the ﬁve inhibitors for CLK1, CLK2,
CLK3, and DYRK1A. Literature values for TG003 according to
Muraki et al.:21 CLK1, 20 nM; CLK2, 200 nM; CLK3, >10 μM;
CLK4, 15 nM. Literature values for TG003 according to Fedorov et
al.:14 CLK1, 48.6 nM; CLK3, >4 μM; Dyrk1A, 156.1 nM. Literature
values for TG003 according to Mott et al.:26 CLK1, 19 nM; CLK2, 95
nM; CLK3, 3 μM; CLK4, 30 nM; Dyrk1A, 12 nM.
Biochemistry Article
DOI: 10.1021/acs.biochem.5b01128
Biochemistry 2016, 55, 608−617
612
benzobisthiazole docked into the adenine binding site, with the
nitrogen atom in the ring making a hydrogen bond to the
backbone NH group of L246 (Figure 5B) as in the case of
NR9. The methyl group of the benzobisthiazole docked into
hydrophobic pocket I. The benzothiazole ended up in
hydrophobic pocket II. Compared to NR9, it lacks the
hydrogen bond formed with K193. However, the extra
hydrophobic interaction in pocket II may explain the more
potent and speciﬁc inhibition of 3A5 over NR9. The structure
of 3A5 contains a benzobisthiazole scaﬀold and a benzothiazole
joined by an amide bond. One could speculate that an inverse
binding mode is possible; e.g., the benzothiazole binds in the
hinge region. Although the two ring systems are similar, they
are quite diﬀerent in size, the former being a tricyclic ring and
the latter a bicyclic. This will have an eﬀect in the docking
experiment. In fact, in our docking results, only one of 10
solutions was an inverse binding pose, and the docking score
was the worst. This is mainly because the hydrophobic
interaction between the protein and the larger benzobisthiazole
is weakened.
On the other hand, the inhibitions of 5E4 and 5F4 against
CLK2 are decreased ∼2−3-fold compared to that of 3A5. The
benzobisthiazole scaﬀolds of 5E4 and 5F4 are slightly diﬀerent
isomeric types compared to that of 3A5. Some of the relevant
heteroatoms are in diﬀerent positions in these two chemotypes,
so it may not be surprising that a diﬀerent aﬃnity for the
enzyme is observed. However, because there is an extra
thiomethyl (-SCH3) attached to the ring of 5E4 and 5F4,
instead of a methyl (-CH3) as in 3A5, it could also inﬂuence the
interaction between the molecule and the protein. From the
docking result, to balance the hydrophobic interaction with the
kinase, 5E4 does not form a hydrogen bond with hinge L246,
but instead a hydrogen bond can be formed with the D327 side
chain in CLK2 (Figure 5B). 5F4 is slightly larger than 5E4, and
the extension of the molecule makes the overall structure less
planar. Although 5F4 is predicted to form a hydrogen bond
with hinge L246, the carbonyl group (CO) seems to have a
negative eﬀect on the overall binding as it is not optimally
occupying a pocket with the backbone CO group of E294.
Thus, the binding mode of 3A5, 5E4, and 5F4 diﬀers
considerably, with the benzobisthiazole contributing signiﬁ-
cantly to the overall kinase binding.
Of the ﬁve inhibitors used in this study, only 3A5 is a potent
inhibitor of CLK3 with an IC50 of 346 nM (Table 2). To
rationalize this, the ﬁve inhibitors were docked against a
structure of CLK3 (PDB entry 2WU6). In the X-ray crystal
structure of CLK3, the cocrystallized inhibitor DKI (K00546)
forms three bidentate hydrogen bonds with the backbone E237
and L239 (Figure 5D).14 The phenylsulfonamide binds in
hydrophobic pocket I while the diﬂuorophenyl in hydrophobic
pocket II. DKI binds in a DFG-in conformation of classic kinase
binding sites. The docking results indicated that only 3A5 can
form the classic bidentate hydrogen bonding with the backbone
L239 (Figure 5C). The benzothiazole occupies hydrophobic
region II. Other inhibitors such as TG003, NR9, 5E4, and 5F4
cannot form any hydrogen bond at the hinge region (Figure
Figure 3. Overview of the CLK2 kinase domain structure. (A) Structural superimposition of CLK1 (PDB entry 2VAG), CLK2 (PDB entry 3NR9),
CLK3 (PDB entry 2WU6), and Dyrk1A (PDB entry 4MQ1), colored red, blue, green, and orange, respectively. The dashed squared box indicates
the ATP binding pocket of the kinases. (B) Ribbon diagram representation of the CLK2 kinase domain in a trimeric structure. The secondary
structures are shown as yellow β sheets and red helices, and the NR9 inhibitors are colored blue. (C) Surface of the ATP binding pocket of CLK2
showing negatively charged amino acid residue surfaces in red, positively charged residues in blue, polar residues in cyan, hydrophobic residues in
green, and phenylalanine residues in yellow. ATP binding and catalytic sites are denoted by the dashed and solid oval, respectively. Figures were
generated using PyMOL.22
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5E). The absence of the bidentate bond may explain the
inactivity of these inhibitors toward CLK3.
3A5 had a stronger inhibitory eﬀect against CLK2 (IC50 = 68
nM) than against CLK3 (IC50 = 346 nM), though it formed
more hydrogen bonds with CLK3 than with CLK2 (panels C
and A of Figure 5). For the investigation, we examined the
binding pose of the inhibitor in the kinases (Figure 6). We
found that the hydrophobic interaction between 3A5 and
CLK2 was stronger than that between 3A5 and CLK3. This
phenomenon is well-supported by the similarity of their ATP
binding pockets (Figure 3A).
■ DISCUSSION
CLK2 has emerged as a promising drug target in a variety of
diseases, including neurodegeneration and virus infection.6−8
The crystal structure of CLK2 in complex with NR9 is available,
Figure 4.Multiple-sequence alignment of the catalytic domain of human CLK1, CLK2, CLK3, CLK4, and Dyrk1A. Amino acid residues contributing
to the surface of the ATP binding pocket are colored as follows: red, blue, cyan, green, and yellow for negatively charged, positively charged, polar
amino acid, hydrophobic, and phenylalanine residues, respectively. Arrows indicate amino acid residues that contribute signiﬁcantly to the formation
of the ATP binding pocket of the kinases. The multiple-sequence alignment was prepared by ClustalW2.
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but no further information regarding how the structure relates
to activity has been reported. Here, we employed a small
molecule screen, involving 1600 compounds from the CUTE
LIFE Chemicals kinase inhibitor library, to identify new potent
inhibitors of CLK2. As a result, we identiﬁed the
benzobisthiazole scaﬀold as a potent inhibitory structure for
CLK2 and other CLK family members. The benzobisthiazole
scaﬀold has previously been reported in novel bacterial helicase
inhibitors,27 thus showing promise for further drug develop-
ment. A substructure search of the benzobisthiazole (Figure
2D) moiety in ChEMBL28 revealed that this scaﬀold is novel
among around 54K known kinase inhibitors.
The novel benzobisthiazoles displayed remarkable potency in
inhibition of CLK1, CLK2, and DYRK1A, supporting the
notion that this scaﬀold is a good starting point for the
development of inhibitors for the CLK family of proteins.
Interestingly, of the three benzobisthiazoles, only compound
3A5 displayed signiﬁcant inhibitory activity toward CLK3. We
propose that this selectivity is mediated by an interaction of the
benzobisthiazole of 3A5 with L239 in the backbone of CLK3,
Figure 5. Docking models of small molecules in the ATP binding site of CLK2 and CLK3. (A) Predicted binding pose of 3A5 (C atoms colored
cyan) in CLK2. A hydrogen bond is formed between the backbone NH group of L246 and the nitrogen atom in the benzobisthiazole ring. The ATP
binding site is shown as a yellow surface. (B) Predicted binding poses for 5E4 (C atoms colored magenta) and 5F4 (C atoms colored orange) in
CLK2. (C) Predicted binding pose for 3A5 (C atoms colored cyan) in CLK3 (PDB entry 2WU6, C atoms colored purple). Only the hinge region is
shown. (D) Cocrystallized DKI (K00546, C atoms colored brown) in CLK3 (PDB entry 2WU6, C atoms colored purple). (E) Predicted binding
pose for 5E4 (C atoms colored magenta), 5F4 (C atoms colored orange), NR9 (C atoms colored green), and TG003 (C atoms colored pink) in
CLK3 (PDB entry 2WU6, C atoms colored purple). Only the hinge region is shown.
Figure 6. Interaction diagram of 3A5 in the ATP binding site of (A) CLK3 and (B) CLK2. (A) Predicted binding pose of 3A5 in CLK3. There are
three H-bonds formed between the ligand and E237, L238, and L239 of CLK3 beside polar interaction with K241, S294, and K186 and hydrophobic
interaction with A184, V220, F236, V170, L290, and L162. (B) Predicted binding pose of 3A5 in CLK2. A hydrogen bond is formed between the
backbone NH group of L246 and the nitrogen atom in the benzobisthiazole. There are strong hydrophobic interactions between the ligand and
L245, L246, A191, F243, V227, V326, V177, L297, L169, and F174 of CLK2 in addition to polar contact between the ligand and E171, K292, and
D327.
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thus allowing classic bidentate hydrogen bonding with CLK3,
and further modiﬁcation of the hinge region binding29 of 3A5
would enable us to obtain a very potent and selective
benzobisthiazole-based inhibitor against CLK3. The underlying
diﬀerence in binding compared to that of 5E4 and 5F4 is based
on the diﬀerent heteroatom arrangement in the benzobisthia-
zole scaﬀolds (see Figures 2 and 3B): The core scaﬀold of the
hits is a tricyclic benzobisthiazole. For 3A5, the most potent
inhibitor of CLK2, the two sulfur atoms are in positions 2 and 4
of the ring system (benzo[1,2-d:3,4′]bisthiazole). In this case,
the two sulfur atoms are not on the same side of the ring
system. In 5E4 and 5F4, the two sulfur atoms are in the 2,3
position of the ring system (benzo[1,2-d:4,3′]bisthiazole) and
the two sulfur atoms are on the same side of the ring system.
Their docking results against CLK2 are quite diﬀerent. This
could be due to the diﬀerent arrangement of the position of the
heteroatoms, the groups attached to the amide linker, the
strong hydrophobic pocket of CLK2 toward the compound
with a benzobisthiazole scaﬀold, and the overall shape of the
molecule. Similar to this study, a previous study also noted
substantial diﬀerences in inhibitor binding for CLK1 compared
to the structure of CLK3.14 This was attributed to a preference
for CLK3 to undergo conformational changes with the P loop
moving away from the ATP binding site upon inhibitor
binding. Similar conformational changes may contribute to
diﬀerential binding of the benzobisthiazoles to CLK2 and
CLK3. Future studies using cocrystallization can prove this
theory.
In summary, our study identiﬁed a novel chemical motif, the
benzobisthiazole, as a selective and potent inhibitor for CLK
family members. These studies will be informative in the future
for selecting and modeling better compounds to improve
selectivity toward the CLK family.
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